Were still figuring out exactly how these GLP-1 agonists affect stem cells and fat compartments
The factors below are based on research with standard-dose GLP-1 and should not be interpreted as direct evidence of microdosing efficacy
Needle phobia Unsurprisingly, many users of subcutaneous GLP-1 RAs find regular injections inconvenient, the injections painful, the needles too large, or they prefer oral medications
While there is some existing research on berberine as a standalone supplement, the evidence doesn't support the idea that it works as effectively as a prescription GLP-1 medication , and studies on the transdermal delivery method (absorbing supplements through the skin) for these ingredients are lacking
References inline (PubMed / NEJM citations as available)
GLP-1(936) inhibits glucagon secretion equally regardless of stimulus The finding that GLP-1(936) retains its glucagonostatic capacity in the presence of 8-Br-Rp-cAMPS suggests that this action is not mediated by inhibition of PKA